Image credit Weight loss is an incredible journey; if you’ve been through it, you know how frustrating and overwhelmin ...

Eli Lilly's weight-loss drug Zepbound and diabetes medication Mounjaro are no longer in short supply. That could limit ...

The San Francisco telehealth company had capitalized on the shortage by making copycat versions of popular brand-name GLP-1 ...

The shortage of Eli Lilly’s (LLY) blockbuster diabetes and weight loss drugs is officially over, according to the U.S. Food ...

Hims & Hers shares tanked after regulators signaled new limits on the production of versions of weight-loss drugs.

Wegovy and Zepbound are still hard to get. Knockoff versions from Noom, Ro, and others are filing in the gaps.

While Ozempic is rising in popularity, experts say the drug is not designed or approved for weight loss. (Oct. 3, 2024) ...

Hims & Hers' (HIMS) stock drop marks the latest overhang on a company that has more than doubled in value over the past 12 ...

The FDA says the shortage of tirzepatide injection — a glucagon-like peptide 1 medication used for diabetes and weight loss — ...

NBC 7 dives deep into the explosive popularity of the medications and explores both the life-changing benefits and the ...

Some fear weight-loss stocks are approaching bubble territory, but this incumbent player continues to prove its worth ...

Novo Nordisk and Eli Lilly are currently dominating the weight loss drug market ... to account for roughly $70 billion of the total GLP-1 market, which is expected to be worth $200 billion ...